文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

英夫利西单抗治疗重症COVID-19患者(INFLIXCOVID):一项随机、对照、多中心、开放标签II期临床研究方案

Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study.
PubMed 文献 · Trials · 2022-09-02

该II期临床试验将具有高炎症临床和实验室证据的COVID-19患者随机分配至英夫利西单抗(5 mg/kg体重)联合标准治疗组或单纯标准治疗组,主要终点为28天死亡率差异,同时评估安全性和对疾病病程的影响,并采集血尿样本进行分子变化研究。

要点

  • 重症COVID-19以IL-6和TNF-α等促炎细胞因子释放驱动的全身炎症反应为特征。
  • 英夫利西单抗为靶向TNF-α的单克隆抗体,此前尚无评估其治疗COVID-19有效性及安全性的随机对照试验结果发表。
  • 该II期试验主要终点为28天死亡率差异,并评估英夫利西单抗在COVID-19中的安全性及对疾病病程的影响。

核心结论

  • 该研究结果可能影响COVID-19患者的治疗,并因英夫利西单抗全球可及且已获多个国际药品机构批准而可能影响全球疾病进程。

研究设计与样本

  • II期随机、对照、多中心、开放标签临床研究。
  • 研究对象为具有高炎症临床和实验室证据的COVID-19患者。
  • 患者随机接受单剂英夫利西单抗(5 mg/kg体重)联合标准治疗或单纯标准治疗。
  • 主要终点为28天死亡率差异;进一步评估英夫利西单抗在COVID-19中的安全性及其对患病率和疾病病程的影响。
  • 补充科学程序采集血液和尿液样本以评估伴随的分子变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the intense global research endeavour to improve the treatment of patients with COVID-19, the current therapy remains insufficient, resulting in persisting high mortality. Severe cases are characterised by a systemic inflammatory reaction driven by the release of pro-inflammatory cytokines such as IL-6 and tumour-necrosis-factor alpha (TNF-α). TNF-α-blocking therapies have proved beneficial in patients with chronic inflammatory diseases and could therefore pose a new treatment option in COVID-19. Hitherto, no results from randomised controlled trials assessing the effectiveness and safety of infliximab-a monoclonal antibody targeting TNF-α-in the treatment of COVID-19 have been published. METHODS: In this phase-2 clinical trial, patients with COVID-19 and clinical and laboratory signs of hyperinflammation will be randomised to receive either one dose of infliximab (5 mg/kg body weight) in addition to the standard of care or the standard of care alone. The primary endpoint is the difference in 28-day mortality. Further assessments concern the safety of infliximab therapy in COVID-19 and the influence of infliximab on morbidity and the course of the disease. For the supplementary scientific programme, blood and urine samples are collected to assess concomitant molecular changes. The Ethics Committee of the Friedrich Schiller University Jena (2021-2236-AMG-ff) and the Paul-Ehrlich-Institute (4513/01) approved the study. DISCUSSION: The results of this study could influence the therapy of patients with COVID-19 and affect the course of the disease worldwide, as infliximab is globally available and approved by several international drug agencies. TRIAL REGISTRATION: The trial was registered at clinicaltrials.gov ( NCT04922827 , 11 June 2021) and at EudraCT ( 2021-002098-25 , 19 May 2021).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Coldewey SM, Neu C, Bloos F, et al. Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study. Trials. 2022. PMID: 36056419. doi:10.1186/s13063-022-06566-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。